Subtype-specific regulation of P2X3 and P2X2/3 receptors by phosphoinositides in peripheral nociceptors by unknown
BioMed CentralMolecular Pain
ssOpen AcceResearch
Subtype-specific regulation of P2X3 and P2X2/3 receptors by 
phosphoinositides in peripheral nociceptors
Gary Mo†1,3, Louis-Philippe Bernier†1, Qi Zhao2, Anne-Julie Chabot-Doré1, 
Ariel R Ase1, Diomedes Logothetis2, Chang-Qing Cao3 and 
Philippe Séguéla*1
Address: 1Montreal Neurological Institute, Department of Neurology & Neurosurgery, McGill University, Montreal, Canada, 2Department of 
Structural and Chemical Biology, Mount Sinai School of Medicine, New York, USA and 3Department of Bioscience, AstraZeneca R&D Montreal, 
Montreal, Canada
Email: Gary Mo - gary.mo@mail.mcgill.ca; Louis-Philippe Bernier - louis-philippe.bernier@mail.mcgill.ca; Qi Zhao - zandq18_98@yahoo.com; 
Anne-Julie Chabot-Doré - anne-julie.chabot-dore@mail.mcgill.ca; Ariel R Ase - arielase@yahoo.com; 
Diomedes Logothetis - delogothetis@vcu.edu; Chang-Qing Cao - ChangQing.Cao@astrazeneca.com; 
Philippe Séguéla* - philippe.seguela@mcgill.ca
* Corresponding author    †Equal contributors
Abstract
Background: P2X3 and P2X2/3 purinergic receptor-channels, expressed in primary sensory
neurons that mediate nociception, have been implicated in neuropathic and inflammatory pain
responses. The phospholipids phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol
3,4,5-trisphosphate (PIP3) are involved in functional modulation of several types of ion channels.
We report here evidence that these phospholipids are able to modulate the function of homomeric
P2X3 and heteromeric P2X2/3 purinoceptors expressed in dorsal root ganglion (DRG)
nociceptors and in heterologous expression systems.
Results: In dissociated rat DRG neurons, incubation with the PI3K/PI4K inhibitor wortmannin at
35 μM induced a dramatic decrease in the amplitude of ATP- or α,β-meATP-evoked P2X3
currents, while incubation with 100 nM wortmannin (selective PI3K inhibition) produced no
significant effect. Intracellular application of PIP2 was able to fully reverse the inhibition of P2X3
currents induced by wortmannin. In Xenopus oocytes and in HEK293 cells expressing recombinant
P2X3, 35 μM wortmannin incubation induced a significant decrease in the rate of receptor
recovery. Native and recombinant P2X2/3 receptor-mediated currents were inhibited by
incubation with wortmannin both at 35 μM and 100 nM. The decrease of P2X2/3 current amplitude
induced by wortmannin could be partially reversed by application of PIP2 or PIP3, indicating a
sensitivity to both phosphoinositides in DRG neurons and Xenopus oocytes. Using a lipid binding
assay, we demonstrate that the C-terminus of the P2X2 subunit binds directly to PIP2, PIP3 and
other phosphoinositides. In contrast, no direct binding was detected between the C-terminus of
P2X3 subunit and phosphoinositides.
Conclusion: Our findings indicate a functional regulation of homomeric P2X3 and heteromeric
P2X2/3 ATP receptors by phosphoinositides in the plasma membrane of DRG nociceptors, based
on subtype-specific mechanisms of direct and indirect lipid sensing.
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P2X receptors are nonselective cation channels gated by
ATP and expressed on a variety of cell types in mammals,
including neurons, glia, epithelial cells and smooth mus-
cle cells [1,2]. In mammals, seven subunits (P2X1-7, new
NC-IUPHAR nomenclature) have been identified, which
associate to form homo- and heterotrimeric receptor-
channels [3-6]. Extensive evidence indicates that P2X
receptors are involved in both peripheral and spinal pain
transmission [7-9]. Particularly, the expression of the
P2X3 subtype is selective for the non-peptidergic small-
diameter dorsal root ganglion (DRG) neurons, which are
associated with nociceptive transmission [10-12]. In vivo
studies have provided evidence that the activation of
homomeric P2X3 and heteromeric P2X2/3 ATP receptors
contributes to acute nociceptive behavior, hyperalgesia
and allodynia [13-15].
Much attention has been brought to phosphoinositides as
major signaling molecules at plasma membranes. The
precursor of all phosphoinositides, phosphatidylinositol
(PI), is the most abundant, followed by PI(4,5)P2 (PIP2)
and PI4P, each comprising 1% of the total phospholipids
in the plasma membrane. PI(3,4,5)P3 (PIP3) is considera-
bly less abundant. These phospholipids are produced by
selective lipid kinases, namely phosphoinositol 3-kinase
(PI3K), phosphoinositol 4-kinase (PI4K) and phosphoi-
nositol 5-kinase, which phosphorylate the inositol ring at
the 3', 4' or 5' positions. Synthesis of PIP2 is completed
through successive phosphorylations by PI4K and phos-
phoinositol(4) 5-kinase. Formation of PIP3 from PIP2
requires additional phosphorylation by PI3K. Phosphoi-
nositides exert their regulatory role either indirectly, for
example as precursors of the phospholipase C-generated
second messengers inositol 1,4,5-trisphosphate and dia-
cylglycerol, or directly by interacting with membrane pro-
teins via electrostatic binding to positively charged
residues, thus controlling their subcellular localization
and/or their activity [16,17].
Recent studies have revealed an increasing number of ion
channels interacting with phosphoinositides, including
Kir [18], TRP [19], P2X [20], NMDA [21] and BK [22]. Fol-
lowing the work of Fujiwara and Kubo [23] on the modu-
lation of P2X2 receptors by phosphoinositides, other P2X
receptors were found to be sensitive to phospholipids [24-
26]. The present study explored the functional interaction
of PIP2 and PIP3 with native and heterologously expressed
P2X3 and P2X2/3 receptor-channels and its physiological
consequences. Using isolated DRG neurons in culture and
patch-clamp recording, we report a strong modulation of
homomeric P2X3- and heteromeric P2X2/3-mediated
responses by wortmannin-induced phosphoinositide
depletion. By means of two-electrode voltage-clamp and
inside-out patch recordings in the Xenopus laevis oocyte
expression system, we also provide functional evidence
that PIP2 and PIP3 modulate the speed of recovery of P2X3
and P2X2/3 receptor channels. Finally, using an in vitro
lipid binding assay we show that the binding of phos-
pholipids to P2X3 subunit is likely indirect. The proximal
C-terminal region of P2X2 subunit directly interacts with
several anionic phospholipids, including PIP2, and thus
confers direct phospholipid modulation to the hetero-
meric P2X2/3 receptor channels.
Methods
Cell Culturing and mutagenesis
DRGs from lumbar segments were extracted from
Sprague-Dawley rats age 4–6 weeks (Charles River Can-
ada) under deep anaesthesia induced by halothane
(Sigma-Aldrich). Extracted DRGs were placed in ice-cold
oxygenated DMEM (Gibco) for removal of connected tis-
sue and dura matter. The isolated DRGs were then placed
into DMEM containing 1 mg/mL of papain and 2 mg/mL
collagenase type II (both from Sigma Aldrich) and incu-
bated for 1 h at 37°C. After enzymatic digestion, the
DRGs were transferred into DMEM containing 10% FBS
and 1% L-glutamine, dissociated into single neurons by
means of trituration using fire-polished pipettes. Dissoci-
ated neurons were then plated onto 35 mm cell culture
dishes (Sarstedt) coated with laminin (BD Bioscience)
and poly-D-lysine (Sigma-Aldrich), and cultured for 48 h
at 37°C and 100% humidity in F-12 media (Gibco) con-
taining 10% FBS, 1% L-glutamine and 100 U/mL penicil-
lin and streptomycin. The culturing media was also
supplemented with 30 ng/mL of NGF (Sigma-Aldrich).
Culturing media for the HEK293 cells was DMEM supple-
mented with 10% fetal bovine serum, 1% penicillin and
streptomycin, 1% MEM non-essential amino acids, and
1% glutamine (all from Gibco). HEK293 cells were tran-
siently cotransfected with EGFP and wild-type or mutant
rat P2X3 in pcDNA3 using PolyFect Transfection Reagent
(Qiagen) according to the manufacturer's instructions.
Residues K348, K354, R356, K357, and R367 of P2X3
were mutated into glutamine using Quikchange (Strata-
gene) site-directed mutagenesis and mutations were con-
firmed by sequencing.
Patch-clamp recordings in DRG neurons and transfected 
HEK293 cells
Whole-cell patch-clamp recordings (Vh of -60 mV) on
DRG neurons were conducted using pipettes filled with
internal solution, pH 7.2, containing (in mM): 130 K-glu-
conate, 1 MgCl2, 5 EGTA, 10 HEPES, 3 MgATP, and 0.4
GTP. Drug applications were performed using a fast
microperfusion system at a rate of 1 mL/min (SF-77B,
Warner Instruments, Morris Plains, NJ). The standard per-
fusion solution, pH 7.4, comprised (in mM): 152 NaCl, 5
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose.
HEK293 cells were used for electrophysiological record-Page 2 of 13
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solution contained (in mM): 120 K-gluconate, 1 MgCl2, 4
NaOH, and 10 HEPES (pH 7.2). The perfusion solution,
pH 7.4, comprised (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 2
MgCl2, 10 HEPES, and 10 glucose. Membrane currents
were recorded using an Axopatch 200B amplifier, digi-
tized with a Digidata 3200A interface (Axon Instruments,
Foster City, CA.), and acquired at a frequency of 2 kHz
using pClamp 9. Osmolarity of external solutions were
adjusted to 300 mOsm and that of pipette solutions to
280 mOsm. All experiments were carried out at room tem-
perature (20–23°C). Recording electrodes were produced
by pulling borosilicate glass tubes using a P-97 puller
(both from Sutter Instrument, Novato, CA.), and fire-pol-
ishing with a MP-830 microforge (Narishige, Tokyo,
Japan) to a tip resistance of 3–6 MΩ when filled with ICS.
The culturing chambers were also used as the recording
chamber. Results were expressed as amplitude of peak cur-
rents evoked by α,β-meATP or as current density, defined
as the ratio of peak amplitude over membrane capacitance
(pA/pF). For measuring recovery, the amplitude of the
third P2X3 response was compared to the first and
expressed as a percentage (rundown ratio). The results
obtained after 2 h drug incubation were always compared
to those obtained after 2 h incubation in culturing media
containing DMSO (vehicle). Membrane capacitance (Cm)
and series resistance (Rs) were measured through the peak
amplitude and decay constant of transients induced by
repetitive depolarizing pulses of 10 mV.
Voltage-clamp and macropatch recordings in Xenopus 
oocytes
Oocytes were surgically removed from Tricaine-anesthe-
tized female Xenopus laevis frogs and were incubated in
OR2 solution containing 1–2 mg/ml type IA collagenase
at room temperature for 2 h under agitation. Stage V and
VI oocytes were then manually defolliculated before
nuclear or cytoplasmic microinjection of plasmid DNA
coding for P2X2 (5 ng) and tandem P2X2/3 (5 ng) or
mRNA coding for P2X3 (40 ng). After injection, oocytes
were incubated in Barth's solution containing 1.8 mM
CaCl2 at 19°C for 24 to 48 h before electrophysiological
recordings. Two-electrode voltage-clamp recordings (Vh =
-60 mV) were performed using glass pipettes (1–3 MΩ)
filled with 3 M KCl solution. Oocytes were placed in a
recording chamber and perfused at a flow rate of 10 to 12
ml/min with Ringer's solution, pH 7.4, containing (in
mM): 115 NaCl, 5 NaOH, 2.5 KCl, 1.8 CaCl2, and 10
HEPES. Membrane currents (d.c., 1 kHz) were recorded
using a Warner OC-725C amplifier (Warner Instrument,
Hamden, CT) and digitized at 500 Hz. Agonists were dis-
solved in the perfusion solution and applied using a com-
puter-driven valve system. All recordings consisted of
successive applications of α,β-meATP (10 μM) 4 min
apart. Dioctanoyl (diC8)-phospholipids were dissolved in
PBS, and 25 nL were injected in order to reach an intracel-
lular concentration of approximately 200 μM. Inside-out
macropatch experiments were performed using an Axo-
patch 200B amplifier (Axon Instruments, Union City,
CA). PClamp 9 was used for data acquisition and analysis.
The vitelline membrane of Xenopus oocytes was removed
using fine forceps before recordings. Electrodes with
resistance of 0.5–1.0 MΩ were used. The currents were
evoked by ramps from -100 mV to +100 mV. The time-
course of the currents was analyzed at -80 mV. DiC8-PIP2
was dissolved in the bath solution. The agonist (20 μM
ATP) was applied through a gravity-driven perfusion sys-
tem. For each experiment, a minimum of two batches of
oocytes were tested.
Lipid binding assay
Oligonucleotides coding for the C-terminus (F346-T364,
L344-F358, and F346-H397) or the N-terminus (D5-I23) of
P2X3, or the P2X2 C-terminus (F355-T372), were inserted
into the pGEX-2T vector (New England Biolabs). Induced
GST fusion proteins were isolated on glutathione-sepha-
rose beads. After 4 washing cycles with PBS, the GST-pro-
teins were eluted with 50 mM Tris-Cl (pH 8) + 5 mM
reduced glutathione, and analysed by SDS-PAGE. The
lipid binding analysis of the recombinant GST-fusion pro-
teins was conducted using lipid coated hydrophobic
membranes (PIP Strips™, Echelon Biosciences Inc.). The
membranes were first blocked with TBS+T solution sup-
plemented with 3% BSA for one hour at room tempera-
ture, then incubated overnight in TBS+T with 3% BSA and
1 μg/mL of the GST fusion protein. The membranes were
then washed with TBS+T six times, 5 minute per wash. The
primary antibody (mouse anti-GST, 1:1000) was then
added in TBS+T, 3% BSA solution for one hour. Washes
with TBS+T were repeated, followed by incubation with
the secondary antibody (goat anti-mouse HRP, 1:5000) in
TBS+T, 3% BSA. The membranes were washed again in
TBS+T, and then bound proteins were detected in ECL
(PerkinElmer).
Biotinylation of surface proteins and Western blotting
Transfected HEK293 cells were incubated with Sulfo-
NHS-LC-Biotin (0.5 mg/mL, Pierce). Cells were homoge-
nized and 100 mg of proteins was adsorbed on immobi-
lized streptavidin. Intracellular proteins were collected
from the unbound fraction. Biotinylated proteins were
eluted from the streptavidin beads by boiling, loaded
onto a 10% SDS-PAGE then transferred to a nitrocellulose
membrane. Monoclonal anti-FLAG antibody (1:5000,
Sigma-Aldrich) was used to detect FLAG-tagged P2X3 sub-
units in ECL (GE Healthcare).
Statistical analysis
Data are presented as mean ± S.E.M. All statistical analyses
for the difference in means were carried out usingPage 3 of 13
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ANOVA followed by Bonferroni's multiple comparison
tests. Normalized data were analyzed using nonparamet-
ric Mann-Whitney U test.
Results
Depletion of PIP2 decreases P2X3 current density in DRG 
neurons
We investigated the role phosphoinositides might have
on native P2X3 receptor currents by disrupting the synthe-
sis of PIP3 and/or PIP2with wortmannin in cultured DRG
neurons. Wortmannin, a furanosteroid metabolite of the
fungi Penicillium funiculosum, has been extensively used to
block key lipid kinases in the phosphoinositides synthesis
pathways. It is a potent inhibitor of PI3K at nanomolar
concentrations while it also blocks PI4K at micromolar
concentrations [27,28]. In agreement with Petruska and
coll. [29], small diameter neurons dissociated from adult
rat DRG responded to 10 μM α,β-meATP (Fig. 1A), or 10
μM ATP, with an inward current that rapidly peaked and
decayed to baseline, indicating complete desensitization.
Incubation for 2 h with 35 μM wortmannin caused a 77%
decrease in endogenous P2X3 current activity in response
to 10 μM α,β-meATP compared to vehicle treatment (Fig.
1A, B) without affecting recovery (data not shown). P2X3
activity under control conditions had a current density of
50.0 ± 4.6 pA/pF, while P2X3 activity after wortmannin
incubation had a current density of only 10.2 ± 2.1 pA/pF
(Fig. 1B and Table 1). Treatment of DRG neurons with 35
μM wortmannin did not have any impact on cell capaci-
tance (vehicle-treated: 28.19 ± 0.93 pF; wortmannin-
treated: 26.61 ± 1.82 pF, p = 0.44, N = 34–86), excluding
a non-specific effect of wortmannin on membrane inter-
nalization. Lowering the concentration of wortmannin to
100 nM, whereby it selectively inhibits PI3K, caused no
significant changes in P2X3 activity compared to control.
P2X3 current density following 2 h incubation with 100
nM wortmannin was 48.2 ± 8.3 pA/pF (Fig. 1B).
Intracellular PIP2 rescues native P2X3 current responses 
after wortmannin treatment
To examine the direct involvement of phosphoinositides
in the modulation of P2X3 current responses by wortman-
nin, we carried out experiments in which diC8-PIP2 was
added to the patch pipette solution to reach intracellular
concentrations of 200 μM. Notably, no modulatory effect
of diC8-PIP2 was observed on baseline activity of P2X3
channels (data not shown), suggesting that endogenous
PIP2 is saturating under basal conditions. Nonetheless, the
inhibitory effect on P2X3 channel responses in conditions
of wortmannin-induced depletion was reversed by intrac-
ellular application of the exogenous PIP2 analogue, as
illustrated in Fig. 1B (control: 50.0 ± 4.6 pA/pF; wortman-
nin + diC8- PIP2: 45.4 ± 5.7 pA/pF). Since under normal
and pathological conditions, activation of native P2X
receptors is triggered by endogenous ATP, the above
described experiment was also carried out using ATP as
agonist (Fig. 1C). As expected, P2X3 current responses to
one single application of 10 μM ATP demonstrated the
same sensitivity to both wortmannin and PIP2, as the ones
recorded with 10 μM α,β-meATP (control: 27.9 ± 3.0 pA/
pF; wortmannin: 8.3 ± 1.8 pA/pF; wortmannin + diC8-
PIP2: 27.5 ± 4.4; Fig. 1C).
Depletion of phosphoinositides decreases P2X2/3 current 
density in DRG neurons
Although P2X3 is the predominant P2X receptor subunit
expressed in DRG nociceptors, about one over ten neu-
rons responded with a rapidly-activating and slowly-
desensitizing response (Fig. 2A), attributed to the activa-
tion of heteromeric P2X2/3 receptor channels [30]. Con-
trary to homomeric P2X3 channels expressed in DRG
neurons, α,β-meATP-evoked responses of native hetero-
meric P2X2/3 channels were sensitive to both high as well
as low wortmannin concentration. As shown in Fig. 2A
and 2B, incubation with 35 μM and 100 nM wortmannin
decreased P2X2/3 current responses by 53% and 59% of
control level respectively (control: 8.8 ± 1.1 pF/pA; 35 μM
wortmannin: 4.2 ± 0.6 pF/pA; 100 nM wortmannin: 3.6 ±
0.6 pF/pA, N = 5–6).
Phosphoinositides modulate P2X2/3 receptors in 
heterologous expression system
We also investigated the modulation of heteromeric
P2X2/3 receptors by phosphoinositides by testing the
effect of their depletion on α,β-meATP-evoked currents in
Xenopus oocytes expressing rat P2X2/3 channels. Consist-
ent with the results shown for the heteromeric P2X2/3
receptor recorded in DRG neurons, α,β-meATP-evoked
currents in oocytes were sensitive to high as well as low
wortmannin concentration. As shown in Fig. 3A and 3B, 2
h incubation of the oocytes in 35 μM or 100 nM wortman-
nin significantly decreased P2X2/3 responses by 51% and
34% of control level respectively (Table 2). The magni-
tude of the modulation of P2X2/3 current amplitudes
induced by the two concentrations of wortmannin were
also significantly different (P = 0.0035). We then tested
the effect of 35 μM LY294002, a compound that selec-
tively blocks PIP3 formation. After 2 h incubation, P2X2/
3 current amplitudes were decreased by 24% compared to
Table 1: Differential effects of 35 μM wortmannin treatment on 
P2X3 current amplitude (%) in DRG neurons and recombinant 
expression systems.
Control Wortmannin
DRG neurons 100.0 ± 9.3 20.4 ± 4.2 ***
HEK293 cells 100.0 ± 9.2 107.6 ± 21.0
Xenopus oocytes 92.8 ± 6.3 94.2 ± 12.2
*** P < 0.001Page 4 of 13
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3 current amplitudes was found between the selective
LY294002 and 100 nM of wortmannin. However, at 35
μM wortmannin (PIP3 and PIP2 depletion), current
responses evoked by α,β-meATP were significantly
decreased compared with those under LY294002 treat-
ment (P = 0.0002).
To verify if the effects of wortmannin were directly related
to the levels of phospholipids in the oocyte, we conducted
experiments where diC8-PIP2 or diC8-PIP3 was injected in
the oocyte cytoplasm. Under basal conditions, injection
of both diC8-PIP2 and diC8-PIP3 did not induce any signif-
icant change to the P2X2/3 current responses (data not
shown). However, under depletion conditions with 35
μM wortmannin, diC8-PIP2 injected oocytes showed 42%
decrease in P2X2/3 current amplitudes, compared to the
64% decrease in sham (PBS) injected oocytes (Fig. 3A, B).
The involvement of PIP3 on the modulation of P2X2/3
receptors was also tested in the same manner, and the
strong wortmannin-induced decreased response was com-
pletely rescued by the addition of diC8-PIP3. The decrease
in current amplitude after diC8-PIP3 injection was 16%, a
significantly smaller decrease than what was seen in
sham-injected oocytes (P < 0.0001). Control oocytes that
were injected with PBS and incubated in Barth's solution
were also tested. The injection and incubation procedure
induced a small non-significant decrease in P2X2/3 cur-
rent amplitude (Fig. 3C).
PIP2 rescues P2X3 and P2X2 current responses from 
rundown in excised inside-out macropatches
Electrophysiological measurements in the inside-out mac-
ropatch configuration were also carried out on Xenopus
Sensitivity of native P2X3 receptor activity to PIP2 depletion in DRG neuronsFigure 1
Sensitivity of native P2X3 receptor activity to PIP2 depletion in DRG neurons. A) Typical traces of P2X3 response 
to 10 μM α,β-meATP in DRG nociceptors (left), to 10 μM α,β-meATP after 2 h incubation with wortmannin (middle), to 10 
μM α,β-meATP after 2 h incubation with wortmannin and intracellular application of 200 μM PIP2 (right). B) Quantitative 
results. P2X3 responses to 10 μM α,β-meATP under control conditions, after 2 h incubation with 100 nM wortmannin, 35 μM 
wortmannin, or 35 μM wortmannin with 200 μM PIP2 in the pipette solution (N = 6–13). C) Quantitative results. P2X3 
responses to 10 μM ATP under control conditions, after 2 h incubation with 100 nM wortmannin, 35 μM wortmannin, or 35 
μM wortmannin with 200 μM PIP2 with in the pipette solution (N = 7–18). (***, P < 0.001).Page 5 of 13
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the inside-out configuration was obtained, a gradual cur-
rent rundown was seen due to hydrolysis of PIP2 by lipid
phosphatases. Polylysine was added to induce a further
current rundown by binding anionic phospholipids.
When PIP2 was then applied to the membrane patch fac-
ing the intracellular side of the membrane, it activated
both P2X2 and P2X3 receptors (Fig. 4). Compared to the
small residual currents seen during polylysine-induced
rundown, the strong current increase evoked by PIP2
application was very significant for both P2X subtypes (P
< 0.01, N = 4–9).
No direct binding of phosphoinositides to the P2X3 subunit
Phosphoinositides are negatively charged lipids, therefore
we investigated potential interactions with basic residues
on the intracellular domain of the P2X3 channel subunit
and confirmed P2X2 subunit binding using a lipid strip
assay. The proximal region of the P2X3 C-terminal
domain contains a cluster of basic amino acids, and was a
candidate sequence for phospholipid binding. The F355-
T372 P2X2 peptide as well as the F346-T364 P2X3 peptide
(Fig. 5A) expressed as a GST-fusion protein were tested
against a set of major phospholipids on PIP strips™ (Fig.
5B). Fig. 5C illustrates the typical binding pattern of P2X2
and P2X3 C-terminal peptides. The P2X2 peptide showed
direct binding to all phosphatidylinositol phosphates:
PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2,
Sensitivity of native P2X2/3 receptor activity to PIP3 depletion in DRG neuronsFigure 2
Sensitivity of native P2X2/3 receptor activity to PIP3 depletion in DRG neurons. A) Sample traces demonstrating 
the effects of 35 μM (middle) and 100 nM wortmannin incubation (2 h) (right) on P2X2/3 response to 10 μM α,β-meATP in 
DRG (control on left). B) Pooled data of P2X2/3 responses to 10 μM α,β-meATP under control condition, after 2 h incubation 
with 35 μM or 100 nM wortmannin (N = 5–6). (**, P < 0.01)Page 6 of 13
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Table 2: Inhibitory effects of wortmannin treatment on P2X2/3 current amplitude (%).
Control 100 nM Wortmannin 35 μM Wortmannin
DRG neurons 100.0 ± 12.6 47.2 ± 7.6 ** 40.9 ± 7.0 **
Xenopus oocytes 105.1 ± 5.5 66.3 ± 4.6 *** 49.1 ± 3.2 ***
** P < 0.01, *** P < 0.001
Sensitivity of P2X2/3 currents to changes in PIP2 and PIP3 levels in Xenopus oocytesFigure 3
Sensitivity of P2X2/3 currents to changes in PIP2 and PIP3 levels in Xenopus oocytes. A) Sample traces showing the 
effect of 35 μM wortmannin incubation and the injection of PBS, PIP2 or PIP3 as compared to an initial current recorded prior 
to incubation. B) Pooled data of P2X2/3 responses to 2 h incubation in control solution (Barth's solution with DMSO), in 35 
μM wortmannin, 100 nM wortmannin, or 35 μM LY294002 (N = 10–33). C) Pooled data of P2X2/3 current inhibition by 2 h 
incubation with 35 μM wortmannin in oocytes injected with vehicle, PIP2, and PIP3 (N = 5–17). (**, P < 0.01; ***, P < 0.001)
Molecular Pain 2009, 5:47 http://www.molecularpain.com/content/5/1/47PI(3,4,5)P3. It also showed strong binding to phospha-
tidic acid and phosphatidylserine. On the other hand, the
F346-T364 P2X3 peptide did not bind to any of the lipids
spotted on the membrane. A shorter peptide from the
same region of the P2X3 subunit, L344-F358, and a longer
peptide corresponding to the complete C-terminus, F346-
H397, were also tested and did not show any binding (data
not shown). Similarly, the N-terminal peptide (D5-I23)
showed no phosphoinositide affinity. Increasing the con-
centration of the P2X3 GST fusion proteins from 1 μg/mL
to 5 μg/mL did not result in significant binding.
Phosphoinositides modulate the rundown of P2X3 
receptor currents in heterologous expression systems, 
which was reversed by mutation R356Q
To further investigate the modulation of P2X3 receptor
channels by phosphoinositides observed in DRG, muta-
tion studies were conducted to identify residues on the
P2X3 subunit that are critical for the interaction with PIP2.
Interestingly, we observed that the initial current ampli-
tude of recombinant P2X3 receptors expressed in HEK293
cells and Xenopus oocytes was not sensitive to PIP2 and
PIP3 depletion by incubation with 35 μM wortmannin
PIP2-activated P2X2 and P2X3 currents in excised inside-out macropatches from Xenopus oocytesFigure 4
PIP2-activated P2X2 and P2X3 currents in excised inside-out macropatches from Xenopus oocytes. The pipette 
solution contained ATP at 100 μM for P2X2 and at 30 μM for P2X3. The currents were evoked by voltage ramps from -100 
mV to +100 mV. The traces shown were constructed by connecting the current points at -80 mV. (**, P < 0.01)Page 8 of 13
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a key role in modulation of several P2X receptor subtypes
by phospholipids [20,25,26] so five point mutations
(K348Q, K354Q, R356Q, K357Q, and R367Q) were gen-
erated to target candidate lysine and arginine residues
involved in direct or indirect modulation of P2X3 by
phosphoinositides. Of the five mutant P2X3 channel sub-
units produced, only the K348Q, R356Q and R367Q
mutants responded to 10 μM α,β-meATP. K348Q and
R367Q were indistinguishable from wild-type P2X3 chan-
nels while the mutants K354Q and K357Q were silent
(Fig. 6A). The R356Q mutant displayed a 48% (64.7 ±
14.3 pA/pF) reduction in activity compared to wild-type
P2X3 channel responses (125.2 ± 11.6 pA/pF). To check if
the decreased responses of the R356Q mutant were actu-
ally due to a decreased receptor function rather than a
decreased receptor trafficking, a surface biotinylation
study was performed with all the mutants and the wild-
type P2X3 constructs. Surface protein expression for
HEK293 cells transfected with wild-type P2X3 was not sig-
nificantly different from the one in HEK293 cells trans-
fected with any of the mutants (Fig. 6B).
Using three consecutive applications of 10 μM α,β-meATP
at 4 min intervals we discovered that the recovery of
recombinant P2X3 receptors was sensitive to phosphoi-
The C-terminus of P2X2, but not of P2X3, directly binds phosphoinositidesFigure 5
The C-terminus of P2X2, but not of P2X3, directly binds phosphoinositides. A) Alignment of the proximal C-termini 
of rat P2X2 and P2X3 subunits showing intracellular basic residues candidates for lipid binding. The dashed lines delineate the 
sequences of the peptides used in the lipid binding assay. B) Positions of the different lipids spotted on the membrane. C) Bind-
ing pattern of GST protein alone, GST-P2X2 (F355-T372) and GST-P2X3 (F346-T364) shows that the sequence from P2X2, 
but not from P2X3, directly binds several anionic phospholipids including PIP2 and PIP3.Page 9 of 13
(page number not for citation purposes)
Molecular Pain 2009, 5:47 http://www.molecularpain.com/content/5/1/47nositide depletion (Fig. 6C). Under control conditions, a
4 min washout between each agonist application allowed
recombinant P2X3 receptor responses to almost fully
recover (93.1 ± 4.9%, N = 7), whereas wortmannin-
induced phosphoinositide depletion led to a significantly
decreased recovery (62.6 ± 7.0%, N = 10; P = 0.0053; Fig.
6D and Table 3). The R356Q mutation reversed the sensi-
tivity of recombinant wild-type P2X3 receptor channels to
modulation by PIP2. Incubation with 35 μM wortmannin
for 2 h produced no significant changes to the recovery
rate of currents elicited by 10 μM ATP in HEK293 cells
transfected with the R356Q mutant (Fig. 6D). Incubation
with wortmannin produced no significant changes to the
initial current amplitude of the mutant P2X3 R356Q.
These results indicate a role for the cytoplasmic residue
R356 in the sensitivity of P2X3 to phosphoinositides, pos-
sibly through binding to an unidentified partner protein.
Discussion
Native P2X3 receptor function is sensitive to PIP2 levels
This study identified a novel regulatory role of phosphoi-
nositides in homomeric and heteromeric P2X3-contain-
ing receptor-channels, in native and recombinant forms.
Functional homomeric P2X3 and heteromeric P2X2/3
receptor channels are highly expressed on DRG primary
sensory neurons that transmit nociceptive sensory infor-
mation. Native P2X3 receptor currents evoked in rat DRG
nociceptors by the selective P2X agonist α,β-meATP were
sensitive to high concentrations of wortmannin which
deplete PIP2 and PIP3, but not to low concentrations of
wortmannin which deplete PIP3 only. The addition of
PIP2 into the recording pipette rescued P2X3 peak currents
under wortmannin-induced phosphoinositide-depleted
condition, providing unequivocal evidence for the regula-
tory role of PIP2 on P2X3 receptor activity. Dialysis with
PIP2 analog into the recording pipette did not affect P2X3
currents under basal condition, indicating saturation by
endogenous PIP2 in DRG neurons in primary culture.
Altogether, these data support the involvement of PIP2
over PIP3 on endogenous P2X3 receptor response. Fur-
thermore, the absence of effect in basal conditions on
P2X3 current responses indicates that no unwanted paral-
lel pathways were modulated by the addition of phosph-
oinositides. Increases in intracellular Ca2+ have also been
shown to stimulate PIP2 synthesis via PI4K [31]. PKC was
shown to directly activate PI4K [32] and to promote PIP2
availability [33]. However, preincubation of DRG neu-
rons with 500 nM staurosporine, a wide-spectrum PKC
blocker, did not alter P2X3 currents (data not shown),
indicating there may be another staurosporine-insensitive
mechanism for the saturation of PIP2 levels in cultured
DRG neurons.
Interestingly, we could not reproduce in heterologous
expression systems the effect of PIP2 depletion on the first
current response of native P2X3 receptors. Instead, P2X3
receptors expressed in oocytes and HEK293 cells showed
decreased speed of recovery of receptor responses under
PIP2 depletion condition. Moreover, PIP2 was able to res-
cue P2X3 currents from rundown in excised patches. The
simplest working hypothesis for the difference observed
between recombinant and native P2X3 responses to wort-
mannin-induced depletion of PIP2 is the existence of a
critical component of P2X3 receptor function expressed in
DRG neurons, but absent in Xenopus oocytes and HEK293
cells.
Heteromeric P2X2/3 receptor function is sensitive to PIP3 
levels
The modulation of the heteromeric P2X2/3 receptors by
phosphoinositides was also investigated in native DRG
neurons. A subpopulation of small diameter/nociceptive
DRG neurons has been shown to express α,β-meATP-
evoked currents with slow onset and slowly-desensitizing
responses due to the activation of heteromeric P2X2/3
receptor channels [30]. Our study shows that the effects of
PIP2 and PIP3 depletion on α,β-meATP-evoked P2X2/3
current amplitudes in DRG neurons were the same in
magnitude, indicating that PIP3 played a major role.
Nonetheless, using Xenopus oocytes expressing P2X2/3
receptors, we observed an inhibitory effect on current
amplitudes that was stronger at high than at low wort-
mannin concentrations, and partial with the selective
PI3K inhibitor LY294002. Although PIP3 completely res-
cued tandem P2X2/3 current amplitudes under wortman-
nin-depleting condition, PIP2 was found to have a partial
albeit significant effect. This result further supports a pre-
dominant role of PIP3, but does not exclude PIP2, on the
modulation of P2X2/3 receptors. Fujiwara and coll. [23]
reported that homomeric P2X2 receptor channels were
sensitive to wortmannin and to the PI3K specific inhibitor
LY294002, as decreased current amplitudes were recorded
in Xenopus oocyte expression system. However, taking into
consideration lipid binding to recombinant C-terminal
P2X2 channel constructs, they proposed that PI(3)P and
PI(3,5)P2, rather than PIP2 or PIP3, are the main regulators
of homomeric P2X2 function. Likely due to less stringent
experimental conditions, we show a significant binding of
the C-terminus of P2X2 to PIP2 and PIP3, as well as many
other anionic phospholipids (Fig. 5).
Table 3: Differential effects of 35 μM wortmannin treatment on 
P2X3 current rundown (%) in DRG neurons and recombinant 
expression systems.
Control Wortmannin
DRG neurons 96.0 ± 7.5 92.0 ± 5.3
HEK293 cells 89.9 ± 6.6 59.8 ± 5.4 **
Xenopus oocytes 93.1 ± 4.9 62.6 ± 7.0 **
** P < 0.01Page 10 of 13
(page number not for citation purposes)
Molecular Pain 2009, 5:47 http://www.molecularpain.com/content/5/1/47Phospholipid modulation of P2X3 receptors does not 
involve direct binding
Several groups have reported the direct binding of the P2X
receptors to phospholipid-containing membranes, using
a biochemical approach in which GST-fusion proteins of
various P2X C-terminal domains suspected to mediate the
binding were tested on lipid strips [23,25,26]. To test if
P2X3 modulation involved direct binding to phosphoi-
nositides, GST-fusion proteins coding for the C-terminal
region of P2X3 homologous to the identified phosphoi-
nositide binding region in other P2X receptors were gen-
erated. The C-terminus was a candidate domain as it has
been shown to be involved in the modulatory function of
several P2X receptor channels, most notably their desensi-
tization [23,34,35] and membrane targeting [36-38]. Sur-
prisingly, no binding of the recombinant P2X3 constructs
to any phospholipids could be detected above back-
ground. The N-terminus of the Kir channel family has
been shown to interact with PIP2for their gating modula-
tion [39]. This led us to test the possibility that interaction
between the P2X3 receptor and PIP2 involved its N-termi-
nal domain. Again, no such interaction was observed as
the binding of N-terminal P2X3 constructs to phospholi-
pid membranes was not detected. Therefore P2X3 is the
only member of the P2X family, so far, that does not dis-
play direct binding to phosphoinositides using the lipid
strip assay. We cannot rule out, however, the possibility
that phosphoinositide binding requires the intact P2X3
receptor subunit.
Sensitivity of P2X3 current to PIP2 depletion in HEK293 cells is reversed by R356Q mutationFigure 6
Sensitivity of P2X3 current to PIP2 depletion in HEK293 cells is reversed by R356Q mutation. A) Pooled data of 
wild-type and mutant P2X3 responses to 10 μM ATP expressed in HEK293 cells (N = 5–11). B) Representative surface bioti-
nylation data of wild-type and mutant P2X3 receptor expression. C) Sample traces showing 35 μM wortmannin-induced run-
down of wild-type P2X3 currents in HEK293 cells. D) Quantitative results. Rundown of wild-type and R356Q mutant P2X3 
current in response to 35 μM wortmannin incubation (N = 5–6). (**, P < 0.01).Page 11 of 13
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nositides is not ungrounded. For instance, Michailidis and
coll. [21] have recently shown that the regulation of the
NMDA receptor by PIP2 requires the intracellular proteinα-actinin, which serves as a partner of NMDAR2 subunit
facilitating phospholipid sensing. Moreover, Kim and
coll. [40] have reported a novel protein called PIRT,
expressed in nociceptive neurons of DRG, which binds to
TRPV1 channels and several phosphoinositides, including
PIP2, to modulate TRPV1 activity. Overall, the require-
ment of a specific partner protein mediating the interac-
tion between phosphoinositides and the P2X3 subunit
may explain why the modulatory effects of phosphoi-
nositides on P2X3 receptors seen in DRG neurons was not
observed in HEK293 cells. The expression of a potential
lipid-binding protein linked to P2X3 subunits remains to
be investigated in DRG neurons. Activation of P2X3-con-
taining receptors has been suggested to provide a specific
mechanism wherein ATP released via synaptic transmis-
sion or tissue injury elicits nociception, with potential dis-
crete role for P2X3 and P2X2/3 receptor activation in
acute and chronic pain [13]. Our study provides evidence
that in nociceptors, the function of homomeric P2X3
receptors is primarily modulated by PIP2, whereas the
function of heteromeric P2X2/3 receptors is mostly mod-
ulated by PIP3. P2X receptors are co-expressed with several
classes of metabotropic receptors that regulate phosphoi-
nositide levels through the activation of PI3K or phos-
pholipase C in non-peptidergic DRG nociceptors. So it
will be interesting to investigate the role of a differential
modulation of P2X3-containing receptors by phosphoi-
nositides in pathophysiological processes such as chronic
inflammatory and neuropathic pain. Moreover, searching
for a phospholipid-binding protein partner of P2X3 sub-
units may well pave the way for designing new strategies
to control pathological nociceptive transmission.
Conclusion
This study demonstrates a modulatory role of phosphoi-
nositides on the function of native P2X3 and P2X2/3
purinergic receptors. While the homomeric P2X3 receptor
is sensitive to changes in PIP2 levels only, the P2X2/3
heteromeric receptor is sensitive to changes in both PIP2
and PIP3 levels. Unlike other ionotropic purinoceptors,
including P2X2, which bind directly to phosphoi-
nositides, our findings suggest that P2X3 is modulated by
PIP2 indirectly. Understanding the mechanisms of lipid
sensing that are selective for the P2X3 and P2X2/3 ATP
receptor subtypes in DRG sensory neurons would aid in
elucidating the respective physiological role of these
prominent targets in pain therapeutics.
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